KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Income from Continuing Operations (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Income from Continuing Operations for 16 consecutive years, with 141591000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 203.34% to 141591000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 316955000.0 through Dec 2025, down 28.63% year-over-year, with the annual reading at 316889000.0 for FY2025, 28.64% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 141591000.0 at Halozyme Therapeutics, down from 175258000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 216587000.0 in Q3 2021, with the low at 141591000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 82373950.0, with a median of 79330000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations soared 557.07% in 2021, then plummeted 203.34% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 66770000.0 in 2021, then fell by 13.58% to 57702000.0 in 2022, then skyrocketed by 47.98% to 85388000.0 in 2023, then skyrocketed by 60.46% to 137012000.0 in 2024, then tumbled by 203.34% to 141591000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 141591000.0, 175258000.0, and 165160000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.